Response of AML to Induction Chemotherapy
| Total . | Control Group . | GM-CSF Group . | ||
|---|---|---|---|---|
| . | 161 . | (100%) . | 157 . | (100%) . |
| Complete response | ||||
| After remission induction cycle I | 73 | (45) | 79 | (50) |
| After remission induction cycle I/II | 89 | (55) | 88 | (56) |
| No complete response | ||||
| Early death | 5 | (3) | 0 | (0) |
| Death in hypoplasia | 16 | (10) | 22 | (14) |
| Resistance to chemotherapy | 51 | (32) | 47 | (30) |
| Total . | Control Group . | GM-CSF Group . | ||
|---|---|---|---|---|
| . | 161 . | (100%) . | 157 . | (100%) . |
| Complete response | ||||
| After remission induction cycle I | 73 | (45) | 79 | (50) |
| After remission induction cycle I/II | 89 | (55) | 88 | (56) |
| No complete response | ||||
| Early death | 5 | (3) | 0 | (0) |
| Death in hypoplasia | 16 | (10) | 22 | (14) |
| Resistance to chemotherapy | 51 | (32) | 47 | (30) |
Abbreviations: AML, acute myeloid leukemia; GM-CSF, granulocyte-macrophage colony-stimulating factor.